Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
The closing price of Ionis Pharmaceuticals Inc (NASDAQ: IONS) was $40.16 for the day, down -1.88% from the previous closing price of $40.93. In other words, the price has decreased by -$1.88 from its previous closing price. On the day, 1.53 million shares were traded. IONS stock price reached its highest trading level at $40.8 during the session, while it also had its lowest trading level at $40.06.
Ratios:
Our analysis of IONS’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 7.28 and its Current Ratio is at 7.37. In the meantime, Its Debt-to-Equity ratio is 6.64 whereas as Long-Term Debt/Eq ratio is at 6.49.
On January 02, 2024, BofA Securities Upgraded its rating to Buy which previously was Neutral and also upped its target price recommendation from $52 to $62.
BofA Securities Upgraded its Underperform to Neutral on October 23, 2023, whereas the target price for the stock was revised from $33 to $52.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on May 03 ’24 when KLEIN JOSEPH III sold 6,000 shares for $42.71 per share. The transaction valued at 256,277 led to the insider holds 0 shares of the business.
Baroldi Joseph sold 4,006 shares of IONS for $166,641 on Apr 16 ’24. The EVP, Chief Business Officer now owns 19,631 shares after completing the transaction at $41.60 per share. On Apr 16 ’24, another insider, Birchler Brian, who serves as the EVP, Corp and Development Ops of the company, sold 905 shares for $41.66 each. As a result, the insider received 37,698 and left with 46,156 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, IONS now has a Market Capitalization of 5857175552 and an Enterprise Value of 5792159232. For the stock, the TTM Price-to-Sale (P/S) ratio is 7.54 while its Price-to-Book (P/B) ratio in mrq is 19.75. Its current Enterprise Value per Revenue stands at 7.354 whereas that against EBITDA is -18.145.
Stock Price History:
The Beta on a monthly basis for IONS is 0.37, which has changed by 0.14233887 over the last 52 weeks, in comparison to a change of 0.2537824 over the same period for the S&P500. Over the past 52 weeks, IONS has reached a high of $54.44, while it has fallen to a 52-week low of $34.79. The 50-Day Moving Average of the stock is -6.49%, while the 200-Day Moving Average is calculated to be -11.50%.
Shares Statistics:
IONS traded an average of 1.09M shares per day over the past three months and 923160 shares per day over the past ten days. A total of 144.34M shares are outstanding, with a floating share count of 134.02M. Insiders hold about 8.11% of the company’s shares, while institutions hold 96.91% stake in the company. Shares short for IONS as of 1713139200 were 9534366 with a Short Ratio of 8.78, compared to 1710460800 on 9665680. Therefore, it implies a Short% of Shares Outstanding of 9534366 and a Short% of Float of 7.739999999999999.
Earnings Estimates
The performance of Ionis Pharmaceuticals Inc (IONS) in the stock market is under the watchful eye of 16.0 analysts actively contributing to its current rating.On average, analysts expect EPS of -$1.04 for the current quarter, with a high estimate of -$0.6 and a low estimate of -$1.36, while EPS last year was -$0.6. The consensus estimate for the next quarter is -$0.97, with high estimates of -$0.55 and low estimates of -$1.27.
Analysts are recommending an EPS of between -$2.46 and -$5.32 for the fiscal current year, implying an average EPS of -$3.98. EPS for the following year is -$3.09, with 19.0 analysts recommending between -$0.92 and -$5.04.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 15 analysts. It ranges from a high estimate of $161.9M to a low estimate of $126M. As of the current estimate, Ionis Pharmaceuticals Inc’s year-ago sales were $188MFor the next quarter, 15 analysts are estimating revenue of $157.86M. There is a high estimate of $175.98M for the next quarter, whereas the lowest estimate is $144.26M.
A total of 23 analysts have provided revenue estimates for IONS’s current fiscal year. The highest revenue estimate was $757M, while the lowest revenue estimate was $568M, resulting in an average revenue estimate of $614.8M. In the same quarter a year ago, actual revenue was $787.65MBased on 21 analysts’ estimates, the company’s revenue will be $777.06M in the next fiscal year. The high estimate is $1.17B and the low estimate is $625.27M.
